CTC intelligence company CelLBxHealth plc (AIM: CLBX) reported on Wednesday that it has signed a new Statement of Work (SOW) worth approximately USD65,000 under an existing Master Services Agreement with a US-based pharmaceutical company.

This contract covers processing around 100 patient samples using the company's Parsortix platform to isolate circulating tumour cells for downstream molecular analysis, including mRNA analysis.

CelLBxHealt added that the contract extends its engagement with an established pharmaceutical customer and supports its strategy to expand biopharmaceutical partnerships and recurring commercial opportunities.

Parsortix uses label-free microfluidic technology to recover intact tumour cells from blood samples, supporting biomarker discovery, translational research and cancer drug development.